BLTE PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

BLTE ▼ -16.56% at T+20d

NEUTRAL call ✗ call lost -16.56% · α vs SPY -19.72% · entry $167.42 → $139.70

Next anchor: T+60d in 5w

Last close $139.63 (close Jun 8) · -16.60% from $167.42 entry

Entry anchored
Apr 21, 03:59 PM ET
via Databento tick

T+1d

-1.77%

call -1.77% · α -1.38%

$164.45

settled 7w ago

T+5d

-5.47%

call -5.47% · α -5.52%

$158.27

settled 6w ago

T+20d

-16.56%

call -16.56% · α -19.72%

$139.70

settled 22d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Belite Bio announced the initiation of a rolling NDA submission to the FDA for tinlarebant, a potential treatment for Stargardt disease type 1, supported by Phase 3 DRAGON trial data. The company expects to complete the submission in Q2 2026.

Actionable Insight

Monitor for completion of the NDA submission in Q2 2026 and potential FDA acceptance for review, which could drive sentiment. However, with no near-term revenue catalyst and ongoing R&D costs, the stock reaction may be muted absent further clinical or regulatory developments.

Key Facts

Belite Bio initiated a rolling NDA submission to the FDA for tinlarebant for the treatment of Stargardt disease type 1 (STGD1).
The NDA submission is being conducted under Breakthrough Therapy Designation and FDA-approved rolling review.
Company expects to complete the submission in Q2 2026.
Tinlarebant has shown transformative results in the Phase 3 DRAGON trial, potentially positioning it as the first approved therapy for STGD1.
No financial results or updates on revenue, earnings, or cash runway were provided in this release.

Financial Impact

No material financial impact disclosed; development-stage update without revenue or earnings implications

revenueepscashFlow

Risk Factors

FDA may not approve tinlarebant despite Breakthrough Therapy Designation.
Clinical data may not translate into meaningful clinical benefit required for approval.
Further dilution likely as company prepares for commercialization without current revenue.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3278392

6 reports for BLTE

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+20▲ +13.78%Apr 9, 2026

Filters

Reports for BLTE — sortable, filterable
	Type				Now
May 20, 2026 20d ago	Press Release MIXED ★ 6/10	$143.36 $148.00	▲ +3.24%	▲ +1.43%	$139.63 (−2.60%)
Apr 21, 2026 7w ago	6-K BULLISH ★ 8/10	$167.42 $158.27	▼ −5.47%	▼ −5.52%	$139.63 (−16.60%)
Apr 21, 2026 7w ago	Press Release NEUTRAL ★ 5/10	$167.42 $158.27	▼ −5.47%	▼ −5.52%	$139.63 (−16.60%)
Apr 9, 2026 8w ago	Insider Cluster BEARISH ★ 7/10	$181.17 $158.05	▲ +12.76%	▲ +15.95%	$139.63 (+22.93%)
Apr 9, 2026 8w ago	Insider Cluster BEARISH ★ 6/10	$181.17 $158.05	▲ +12.76%	▲ +15.95%	$139.63 (+22.93%)
Mar 2, 2026 14w ago	Press Release BULLISH ★ 9/10	$177.58 $179.12	▲ +0.87%	▲ +2.07%	$139.63 (−21.37%)

US Market Status

Market Closed — Opens in 7h 10m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access